Nothing 'gainst Time's Scythe Can Make Defense...
- 28 May 2004
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 304 (5675) , 1262-1263
- https://doi.org/10.1126/science.1098965
Abstract
Designing vaccines against viruses or tumor cells that elicit CD8 T cell responses depends on understanding how viral and tumor antigens initiate activation of na�ve CD8 T cells. In his Perspective, Ploegh explores several studies published here ( Norbury et al., Wolkers et al.) and elsewhere that reveal the pathway from viral or tumor antigens to long-lived peptides that are capable of priming CD8 T cells.Keywords
This publication has 8 references indexed in Scilit:
- CD8 + T Cell Cross-Priming via Transfer of Proteasome SubstratesScience, 2004
- Antigen Bias in T Cell Cross-PrimingScience, 2004
- Cellular protein is the source of cross-priming antigenin vivoProceedings of the National Academy of Sciences, 2004
- The ins and outs of cross-presentationNature Immunology, 2003
- Phagosomes are competent organelles for antigen cross-presentationNature, 2003
- ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cellsNature, 2003
- Peptide Diffusion, Protection, and Degradation in Nuclear and Cytoplasmic Compartments before Antigen Presentation by MHC Class IImmunity, 2003
- Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigenNature, 1999